Suprachiasmatic GABAergic inputs to the paraventricular nucleus control plasma glucose concentrations in the rat via sympathetic innervation of the liver.
Daily peak plasma glucose concentrations are attained shortly before awakening. Previous experiments indicated an important role for the biological clock, located in the suprachiasmatic nuclei (SCN), in the genesis of this anticipatory rise in plasma glucose concentrations by controlling hepatic glucose production. Here, we show that stimulation of NMDA receptors, or blockade of GABA receptors in the paraventricular nucleus of the hypothalamus (PVN) of conscious rats, caused a pronounced increase in plasma glucose concentrations. The local administration of TTX in brain areas afferent to the PVN revealed that an important part of the inhibitory inputs to the PVN was derived from the SCN. Using a transneuronal viral-tracing technique, we showed that the SCN is connected to the liver via both branches of the autonomic nervous system (ANS). The combination of a blockade of GABA receptors in the PVN with selective removal of either the sympathetic or parasympathetic branch of the hepatic ANS innervation showed that hyperglycemia produced by PVN stimulation was primarily attributable to an activation of the sympathetic input to the liver. We propose that the daily rise in plasma glucose concentrations is caused by an SCN-mediated withdrawal of GABAergic inputs to sympathetic preautonomic neurons in the PVN, resulting in an increased hepatic glucose production. The remarkable resemblance of the presently proposed control mechanism to that described previously for the control of daily melatonin rhythm suggests that the GABAergic control of sympathetic preautonomic neurons in the PVN is an important pathway for the SCN to control peripheral physiology.
Kalsbeek
Andries
A
Netherlands Institute for Brain Research, 1105 AZ Amsterdam, The Netherlands. A.Kalsbeek@nih.knaw.nl
La Fleur
Susanne
S
Van Heijningen
Caroline
C
Buijs
Ruud M
RM
D000818:Animals; D001370:Axonal Transport; D001640:Bicuculline / Q000494:pharmacology; D001786:Blood Glucose / Q000502:physiology*; D002940:Circadian Rhythm; D003000:Clonidine / Q000494:pharmacology; D003345:Corticosterone / Q000097:blood; D005934:Glucagon / Q000097:blood; D005943:Gluconeogenesis / Q000502:physiology*; D011558:Herpesvirus 1, Suid; D006943:Hyperglycemia / Q000139:chemically induced / Q000503:physiopathology; D007031:Hypothalamus / Q000187:drug effects / Q000502:physiology; D007328:Insulin / Q000097:blood; D007545:Isoproterenol / Q000494:pharmacology; D008099:Liver / Q000294:innervation* / Q000378:metabolism; D008297:Male; D017551:Microdialysis; D009118:Muscimol / Q000494:pharmacology; D016202:N-Methylaspartate / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D017764:Parasympathectomy; D010275:Parasympathetic Nervous System / Q000502:physiology; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D013493:Suprachiasmatic Nucleus / Q000187:drug effects / Q000502:physiology*; D013562:Sympathectomy; D013564:Sympathetic Nervous System / Q000502:physiology*; D013779:Tetrodotoxin / Q000494:pharmacology; D014667:Vasopressins / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology*
D001786:Blood Glucose; D007328:Insulin; D014667:Vasopressins; D009118:Muscimol; D013779:Tetrodotoxin; D005680:gamma-Aminobutyric Acid; D016202:N-Methylaspartate; D005934:Glucagon; D007545:Isoproterenol; D003000:Clonidine; D003345:Corticosterone; D009638:Norepinephrine; D001640:Bicuculline